Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Target Price at $9.43

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.43.

Several equities analysts have recently issued reports on PYXS shares. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Royal Bank of Canada reiterated an "outperform" rating and set a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. William Blair lowered Pyxis Oncology from an "outperform" rating to a "market perform" rating in a report on Thursday, November 21st. Finally, Stephens started coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They set an "overweight" rating and a $13.00 price objective on the stock.

Insider Buying and Selling

In other Pyxis Oncology news, CFO Pamela Ann Connealy bought 88,850 shares of Pyxis Oncology stock in a transaction that occurred on Tuesday, November 26th. The stock was purchased at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the acquisition, the chief financial officer now owns 1,199,143 shares of the company's stock, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PYXS. Bank of New York Mellon Corp grew its holdings in shares of Pyxis Oncology by 92.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company's stock worth $1,031,000 after acquiring an additional 149,522 shares during the last quarter. Rhumbline Advisers purchased a new position in Pyxis Oncology in the 2nd quarter worth about $216,000. American Century Companies Inc. raised its holdings in Pyxis Oncology by 56.0% during the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company's stock worth $193,000 after buying an additional 20,901 shares during the period. Schulhoff & Co. Inc. lifted its stake in Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company's stock valued at $139,000 after buying an additional 20,000 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock worth $4,425,000 after buying an additional 743,499 shares during the period. Institutional investors own 39.09% of the company's stock.

Pyxis Oncology Trading Down 1.1 %

NASDAQ:PYXS traded down $0.02 during mid-day trading on Tuesday, hitting $1.74. The stock had a trading volume of 508,799 shares, compared to its average volume of 613,250. The company has a 50 day simple moving average of $2.52 and a 200-day simple moving average of $3.13. The stock has a market capitalization of $103.47 million, a price-to-earnings ratio of -1.69 and a beta of 1.06. Pyxis Oncology has a 52 week low of $1.49 and a 52 week high of $6.85.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.